Cargando…
Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome
BACKGROUND: Prostate cancer (PCa) is a major health problem worldwide. Taxol derivatives-based chemotherapies or immunotherapies are usually proposed depending on the symptomatic status of the patient. In the case of immunotherapy, tumors develop robust immune escape mechanisms that abolish any prot...
Autores principales: | Tiraboschi, Carolina, Gentilini, Lucas, Velazquez, Carla, Corapi, Enrique, Jaworski, Felipe Martín, Garcia Garcia, José Daniel, Rondón, Yorfer, Chauchereau, Anne, Laderach, Diego José, Compagno, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725099/ https://www.ncbi.nlm.nih.gov/pubmed/33293356 http://dx.doi.org/10.1136/jitc-2020-001535 |
Ejemplares similares
-
Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials
por: Compagno, Daniel, et al.
Publicado: (2020) -
Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer
por: Gentilini, Lucas Daniel, et al.
Publicado: (2017) -
Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers
por: Laderach, Diego J., et al.
Publicado: (2013) -
Delineating the "galectin signature" of the tumor microenvironment
por: Compagno, Daniel, et al.
Publicado: (2013) -
Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity
por: Corapi, Enrique, et al.
Publicado: (2018)